对于急性静脉血栓塞栓症,没有初始肝素引入的埃多克萨班治疗:COMMAND VTE-2注册表的洞察
Yuta Tsujisaka1, Yugo Yamashita2,3, Takeshi Morimoto4
1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Journal of thrombosis and thrombolysis
|May 28, 2025
概括
埃多克萨班可以安全地用于急性静脉血栓塞栓症 (VTE),而不需要初始的肝素. 这项现实研究发现,在接受氨酸入治疗或不接受氨酸入治疗的患者中,结果没有显著差异.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于急性静脉血栓塞栓症 (VTE) 的标准EDOXABAN包装说明书建议初始使用赫巴林抗凝剂.
- 需要现实世界的数据来评估edoxaban的有效性和安全性,而没有这种初始的肝素治疗.
研究的目的:
- 调查edoxaban在治疗急性VTE的有效性和安全性,当在没有先前治疗氨酸的情况下开始时.
- 为了比较接受edoxaban的患者与没有初始氨酸引入的患者之间的临床结果.
主要方法:
- 分析COMMAND VTE Registry-2,一个多中心注册1842急性VTE患者治疗edoxaban在日本.
- 使用初始肝素和不使用初始肝素的组之间的结果比较,仅通过肺栓塞 (PE) 和深静脉血栓塞 (DVT) 分层.
- 倾向性得分匹配被用来平衡组之间的基线特征.
主要成果:
- 对于PE (2.6%与4.2%) 和DVT (2.7%与3.2%) 的非肝素和肝素组之间30天所有原因死亡的累计发病率没有显著差异.
- 在所有死因,复发性VTE或PE (5.8%与8.4%) 和DVT (4.6%与6.4%) 的重大出血的复合结果中没有显著差异.
- 在这个现实世界注册中,大量急性VTE患者在没有初始肝素的情况下接受了edoxaban.
结论:
- 在没有初始肝素引入的情况下,对急性静脉瘤的埃多克萨班治疗在现实世界中似乎是安全和有效的.
- 这些发现表明,省略初始肝素可能是选择VTE患者的可行策略.
- 进一步的研究可以证实这些发现,并指导临床实践关于edoxaban启动.
相关概念视频
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
932
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
932
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
48
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
48
Venous Thrombosis IV: Nursing Management
27
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
27
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
43
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
43


